Summary
4.79 -0.22(-4.30%)05/17/2024
2seventy bio Inc (TSVT)
2seventy bio Inc (TSVT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.62 | 15.65 | -15.81 | -66.61 | -84.83 | -88.07 | 0.00 | -64.18 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 5.03 | |
| Open | 4.99 | |
| High | 5.10 | |
| Low | 4.94 | |
| Volume | 120,103 | |
| Change | 0.08 | |
| Change % | 1.62 | |
| Avg Volume (20 Days) | 1,602,724 | |
| Volume/Avg Volume (20 Days) Ratio | 0.07 | |
| 52 Week Range | 1.62 - 16.17 | |
| Price vs 52 Week High | -68.89% | |
| Price vs 52 Week Low | 210.49% | |
| Range | 0.00 | |
| Gap Up/Down | -0.12 | |
Fundamentals | ||
| Market Capitalization (Mln) | 246 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 51.67 | |
| Book Value | 2.0910 | |
| Earnings Per Share | -13.1810 | |
| EPS Estimate Current Quarter | -2.7100 | |
| EPS Estimate Next Quarter | -3.2700 | |
| EPS Estimate Current Year | -14.2800 | |
| EPS Estimate Next Year | -13.4900 | |
| Diluted EPS (TTM) | -13.1810 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -6.7682 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 48,393,000 | |
| Revenue per share TTM | 2.0710 | |
| Quarterly Revenue Growth (YOY) | 0.0450 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -53,741,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 13.0215 | |
| Revenue Enterprise Value | 16.4481 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 23,369,100 | |
| Shares Float | 21,312,141 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 1.30 | |
| Institutions (%) | 16.61 | |
05/08 15:15 EST - seekingalpha.com
2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript
2seventy bio, Inc. (NASDAQ:TSVT ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Jenn Snyder - Senior Vice President, Corporate Affairs Chip Baird - Chief Executive Officer Vicki Eatwell - Chief Financial Officer Anna Truppel-Hartmann - Chief Medical Officer Conference Call Participants Rabib Chaudhury - Leerink Partners Matt Leskowitz - Goldman Sachs Kelsey Goodwin - Guggenheim Securities Morgan Gryga - Morgan Stanley John Newman - Canaccord Genuity Operator Good day and thank you for standing by. Welcome to the 2seventy bio First Quarter 2024 Earnings Conference Call.
2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript
2seventy bio, Inc. (NASDAQ:TSVT ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Jenn Snyder - Senior Vice President, Corporate Affairs Chip Baird - Chief Executive Officer Vicki Eatwell - Chief Financial Officer Anna Truppel-Hartmann - Chief Medical Officer Conference Call Participants Rabib Chaudhury - Leerink Partners Matt Leskowitz - Goldman Sachs Kelsey Goodwin - Guggenheim Securities Morgan Gryga - Morgan Stanley John Newman - Canaccord Genuity Operator Good day and thank you for standing by. Welcome to the 2seventy bio First Quarter 2024 Earnings Conference Call.
05/08 09:16 EST - zacks.com
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
2seventy bio, Inc. (TSVT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.08 per share a year ago.
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
2seventy bio, Inc. (TSVT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.08 per share a year ago.
05/03 07:00 EST - businesswire.com
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the c.
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the c.
04/24 11:07 EST - zacks.com
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/17 12:05 EST - zacks.com
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
03/20 17:04 EST - businesswire.com
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company's Board of Directors (the “Board”), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy bio's outstanding shares as of 03/20/24. “We are pleased to welcome Eli and Charlie to the 2seventy Bo.
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company's Board of Directors (the “Board”), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy bio's outstanding shares as of 03/20/24. “We are pleased to welcome Eli and Charlie to the 2seventy Bo.
03/05 07:00 EST - businesswire.com
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2023. “In the past weeks and months, 2seventy has made significant changes to our business and cost structure designed to optimize our ability to unlock value for Abecma,” said Chip Baird, incoming CEO. “While Abecma experienced continued competitive headwinds in the fo.
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2023. “In the past weeks and months, 2seventy has made significant changes to our business and cost structure designed to optimize our ability to unlock value for Abecma,” said Chip Baird, incoming CEO. “While Abecma experienced continued competitive headwinds in the fo.
03/04 10:01 EST - zacks.com
Should You Buy 2seventy bio (TSVT) Ahead of Earnings?
2seventy bio (TSVT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Buy 2seventy bio (TSVT) Ahead of Earnings?
2seventy bio (TSVT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
03/01 07:00 EST - businesswire.com
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Members of the management team will also be presenting at the following upcoming investor conferences: TD Cowen 44th Annual Healthcare Conference in Boston, MA on Wednesday, March 6, 2024 at 2:10 p.m. ET Leerink Partners Global Biopharma Conference in Miami, FL on Wednesda.
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Members of the management team will also be presenting at the following upcoming investor conferences: TD Cowen 44th Annual Healthcare Conference in Boston, MA on Wednesday, March 6, 2024 at 2:10 p.m. ET Leerink Partners Global Biopharma Conference in Miami, FL on Wednesda.
02/05 16:05 EST - businesswire.com
2seventy bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will present at the following upcoming investor conferences: Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, the St. Regis New York, fireside chat on Thursday, February 8th at 1:30 p.m. ET Citi's 2024 Virtual Oncology Leadership Summit, Thursday, February 22nd at 3:00 p.m. ET A live webcast will be available via the Investors and Media section of 2seventy bi.
2seventy bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will present at the following upcoming investor conferences: Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, the St. Regis New York, fireside chat on Thursday, February 8th at 1:30 p.m. ET Citi's 2024 Virtual Oncology Leadership Summit, Thursday, February 22nd at 3:00 p.m. ET A live webcast will be available via the Investors and Media section of 2seventy bi.
02/01 09:31 EST - zacks.com
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?
2seventy bio, Inc. (TSVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?
2seventy bio, Inc. (TSVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
01/31 12:15 EST - zacks.com
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
01/30 07:01 EST - businesswire.com
2seventy bio Announces New Strategic Path Forward
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T therapy for multiple myeloma. The actions announced today follow an extensive evaluation of the Company's business and strategic alternatives by its Board of Directors. As a result of this strategic re-alignment, the Company expects annual savings of appr.
2seventy bio Announces New Strategic Path Forward
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T therapy for multiple myeloma. The actions announced today follow an extensive evaluation of the Company's business and strategic alternatives by its Board of Directors. As a result of this strategic re-alignment, the Company expects annual savings of appr.
01/12 13:32 EST - zacks.com
All You Need to Know About 2seventy bio, Inc. (TSVT) Rating Upgrade to Strong Buy
2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About 2seventy bio, Inc. (TSVT) Rating Upgrade to Strong Buy
2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
12/28 08:16 EST - zacks.com
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include DouYu International (DOYU), Regis (RGS), 2seventy bio Inc. (TSVT), atai Life Sciences (ATAI) and GameStop (GME).
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include DouYu International (DOYU), Regis (RGS), 2seventy bio Inc. (TSVT), atai Life Sciences (ATAI) and GameStop (GME).
12/11 07:00 EST - businesswire.com
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December 12, 2023, at 8:00am ET. The event will highlight data presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 9-12, 2023, in San Diego. Participants can access the conference call live via webcast which will be available on the Investors.
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December 12, 2023, at 8:00am ET. The event will highlight data presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 9-12, 2023, in San Diego. Participants can access the conference call live via webcast which will be available on the Investors.
12/06 14:48 EST - pennystocks.com
Best Penny Stocks To Buy? 4 To Watch With Big News This Week
Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.
Best Penny Stocks To Buy? 4 To Watch With Big News This Week
Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.
12/06 14:00 EST - businesswire.com
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the Company”), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value: As we indicated last month, the Board has commenced a process to consider all options to maximize value. This process is well underway and our team is committed to working as thoughtfully and quickly as possible to ensure our important therapies become.
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the Company”), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value: As we indicated last month, the Board has commenced a process to consider all options to maximize value. This process is well underway and our team is committed to working as thoughtfully and quickly as possible to ensure our important therapies become.
12/06 08:51 EST - reuters.com
Engine Capital pushes for changes at cancer therapy developer 2seventy bio
Activist investor Engine Capital on Wednesday sent a letter to the board of cancer therapy developer 2seventy bio , urging a board refresh and the appointment of its chief operating officer Chip Baird as CEO, among other changes.
Engine Capital pushes for changes at cancer therapy developer 2seventy bio
Activist investor Engine Capital on Wednesday sent a letter to the board of cancer therapy developer 2seventy bio , urging a board refresh and the appointment of its chief operating officer Chip Baird as CEO, among other changes.
12/06 08:00 EST - businesswire.com
Engine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder Value
NEW YORK--(BUSINESS WIRE)--Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (Nasdaq: TSVT) (“2seventy” or the “Company”) outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the “Board”). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, “Engine” or “we”), is a meaningful shareholder of 2seventy.
Engine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder Value
NEW YORK--(BUSINESS WIRE)--Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (Nasdaq: TSVT) (“2seventy” or the “Company”) outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the “Board”). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, “Engine” or “we”), is a meaningful shareholder of 2seventy.